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LDL levels. These patients have a decreased life expectancy secondary to sudden death and myocardial
infarction. The clinical course of heFH patients is variable and not directly related to serum LDL levels.
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OVID, Web of Science, and CINAHL with Full Text was conducted using key words: CT angiography/
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were reviewed and included based on relevant criteria. Those relevant articles were assessed using the GRADE
system for quality. Results: Three observational studies met inclusion criteria and were included in this
systematic review. All three studies showed a significant increase in the number of heFH participants with
subclinical CAD as seen on CTCA, with almost one quarter of heFH patients demonstrating severe vessel
occlusion.
Conclusion: These studies indicate the heFH patient are more likely to have subclinical coronary
atherosclerosis. In order to justify the use of CTCA in asymptomatic heFH patients, further research looking
at outcomes of heFH patients diagnosed with early CAD is needed. While CTCA does have the ability to
detect which heFH patients have CAD, whether or not this information, when applied to treatment strategies,
can reduce risk of CAD and mortality has yet to be determined.
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Abstract   
Background:  Heterozygous Familial Hypercholesterolemia (heFH) is an autosomal dominant 
disorder caused by a defect in a low-density lipoprotein (LDL) receptor gene and results in 
drastically elevated serum LDL levels.  These patients have a decreased life expectancy 
secondary to sudden death and myocardial infarction. The clinical course of heFH patients is 
variable and not directly related to serum LDL levels.  Recent studies have also shown that many 
heFH patients with coronary artery disease (CAD) present asymptomatically.  Computed 
tomography coronary angiography (CTCA) is one means of detecting subclinical CAD.  
However, CTCA screening has yet to be proven to improve outcomes in those with 
asymptomatic CAD, but outcomes of heFH patients have yet to be studied specifically.  The 
purpose of this systematic review is to compile research that compares asymptomatic heFH 
populations with healthy adults, and determine if CTCA could be warranted in asymptomatic 
heFH patients.   
 
Method:  A search of Medline-OVID, Web of Science, and CINAHL with Full Text was 
conducted using key words:  CT angiography/angiography/coronary angiography, familial 
hypercholesterolemia and asymptomatic/subclinical.  Studies were reviewed and included based 
on relevant criteria.  Those relevant articles were assessed using the GRADE system for quality. 
 
Results:  Three observational studies met inclusion criteria and were included in this systematic 
review.  All three studies showed a significant increase in the number of heFH participants with 
subclinical CAD as seen on CTCA, with almost one quarter of heFH patients demonstrating 
severe vessel occlusion. 
 
Conclusion:  These studies indicate the heFH patient are more likely to have subclinical 
coronary atherosclerosis.  In order to justify the use of CTCA in asymptomatic heFH patients, 
further research looking at outcomes of heFH patients diagnosed with early CAD is needed.  
While CTCA does have the ability to detect which heFH patients have CAD, whether or not this 
information, when applied to treatment strategies, can reduce risk of CAD and mortality has yet 
to be determined.   
 
Keywords: Familial hypercholesterolemia, coronary artery disease, subclinical, asymptomatic, 
computed tomography coronary angiography, atherosclerosis 
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Asymptomatic Coronary Artery Disease in Adults with Familial 
Hypercholesterolemia and use of Coronary Artery Imaging as a Screening 
Tool 
 
BACKGROUND 
Familial hypercholesterolemia (FH) is a genetic disorder affecting 1 in 500 people.1 Life 
expectancy in those with FH is shortened with mortality resulting from sudden death and 
myocardial infarction.2 Heterozygous familial hypercholesterolemia (heFH) is a disease that 
results from autosomal dominant inheritance of a mutated low-density lipoprotein receptor gene 
causing lifelong elevation of LDL-cholesterol (LDL-c), which may build up in arteries resulting 
in early onset of coronary artery disease (CAD) and excess mortality.3  
Despite elevated cholesterol levels, the clinical course of atherosclerotic manifestations in 
heFH subjects is variable.  One study4 of 526 heFH patients found that coronary heart disease 
(CHD) mortality rates were higher in the age group 20-29 years, suggesting that some FH 
subjects will have early coronary events, while others will develop these very late or not at all. 
 Since the 1990s and in part due to increased use of statin medication, rates of coronary 
and total mortality in FH patients have decreased, though they continue to have higher risk for 
premature CAD.5 Most heFH patients require max dose statin therapy in order to reduce LDL 
levels at least 50%, which most do not achieve.6 Currently, there are other drugs on the market 
that are being used to treat hypercholesterolemia:  niacin, fibrates, bile acid sequesterants, 
ezetimibe and omega-3 fatty acids.  Mechanical removal of LDL-c by apheresis is also an 
effective option, though very expensive and usually reserved for the most severe forms of heFH.7 
However, markers for indicating which heFH patients are a candidate for more extensive therapy 
are limited. 
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Recent studies suggest that a large number of heFH patients have obstructive CAD, but 
remain asymptomatic.8,9 This stresses the need for markers to detect the presence of obstructive 
CAD and the risk of developing CAD, in order to direct treatments strategies of heFH patients.   
One suggested means of detecting subclinical coronary atherosclerosis is by non-invasive 
computed tomography (CT).  CT can be used to assess atherosclerosis in one of two ways: 
coronary artery calcification (CAC) scoring and CT coronary angiography (CTCA).  Coronary 
artery calcification is determined using CT without radiologic contrast and then scored using the 
Agatston score method.  The Agatston calcium score is a rule-based system for scoring the CAC.  
However, the amount of coronary calcium has only a weak association with the extent of 
obstruction in the vessel; with the exception of Agatston scores ≥400, which was associated with 
an increased frequency of perfusion ischemia and obstructive CAD.10,11,12 
CT coronary angiography is a non-invasive means to assess the lumen and walls of 
coronary arteries.  It is performed after injection of radiological contrast in a peripheral vein and 
a CT scanner obtains imaging.  CTCA has high diagnostic accuracy. 13,14 However, there is 
limited data on prognostic implication of CT angiography, and it also exposes the patient to 
higher radiation exposure than CAC scoring methods. Thus, CTCA is not recommended as a 
screening tool in asymptomatic patients by the American Heart Association (AHA).11  
The variability of risk of CHD in adults with heFH stresses the importance of 
asymptomatic CAD detection in order to determine which heFH patients are most likely to 
progress to CHD, and to indicate the need for more aggressive prophylactic measures in such 
patients.  The first step is to determine if there is a significant difference between asymptomatic 
healthy adults and those with heFH.  The purpose of this systematic review is to compile 
research that compares asymptomatic heFH populations with healthy adults, and to determine if 
 - 8 -  
CTCA is warranted in asymptomatic heFH patients. The answer to this question could pave the 
way to determining if early detection and treatment of asymptomatic CAD could reduce lifetime 
risk of CHD, which could warrant use of CTCA or CAC scoring in asymptomatic heFH patients. 
METHODS 
An exhaustive search using both Medline-OVID, Web of Science, and CINAHL search 
engines was performed.  For all of these databases, three individual searches were conducted and 
then combined.  The first search included keywords “CT angiography” or “Angiography” or 
“Coronary angiography.”  The second search was for the term “Familial Hypercholesterolemia.”  
The third search was for key words “asymptomatic” or “subclinical.”  These three searches were 
then combined using AND to find articles that contained all three of the searched keyword 
categories.   
This review included study populations of adults between the ages of 30 and 70.  In all 
included studies the diagnosis of heFH was determined by published standardized clinical 
diagnostic criteria and/or genetic testing.  Patients diagnosed with heFH, as well as control 
groups, had to have no previous diagnosis or symptoms of cardiovascular disease and had to be 
currently asymptomatic for CAD.  Control group participants were excluded if they had LDL-c ≥ 
130 or were currently on lipid lowering therapy.  Other exclusion criteria for both heFH and 
control groups included:  allergy to iodine contrast, renal disease, and irregular heart rhythm.  
Studies performed before December 2003 were excluded. 
Study imaging for all included studies was performed by both non-contrast CT to analyze 
CAC score as determined using the Agatston criteria, as well as CT coronary angiography, using 
iodine contrast.  CTCA was interpreted by at least two independent and blinded observers.     
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Relevant articles were critically appraised using a standardized form and then assessed 
for quality using the Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE)15 as displayed in Table 1.  
RESULTS 
The Medline-OVID search produced 17 results, Web of Science searches produced 18, 
and CINAHL search produced 4.  In total 28 individual papers were produced from the Medline-
OVID, Web of Science and CINHAL search strategies.  Of the published works produced, three 
studies met the criteria based on study demographics and eligibility criteria of the database 
searches:  Neefjes et al,16 Vilades et al,17 and Miname et al.18  These three studies16,17,18 were 
similar in design and methodology, with a few variations. 
Each study16,17,18  looked at CAD in asymptomatic heFH patients by means of Agatston 
calcium score as well as CTCA.  Neefjes et al,16 did not compare heFH patients to healthy 
controls, though it provided more specific results, such as Agatston calcium score stratification 
and had the largest population size (140) of heFH patients.  The types of coronary artery plaques 
present in heFH patients was measured in both Neefjes et al, 16  and Miname et al.18  Significant 
obstruction was defined by Neefjes et al, 16  and Miname et al,18  as obstruction >50%; while 
Vilades et al,17 defined significant obstruction as >70% occlusion.  Coronary artery findings 
detected on CT imaging for heFH patients and control groups from the studies16,17,18 were 
compared (see Table 2). Other variables were also measured in relationship with CAD in 
asymptomatic heFH patients in all three studies.16,17,18  as displayed in Table 3. 
 
CCTA Findings 
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All three studies16, 17,18 found that heFH groups had more frequent CAD than the control 
groups of studies Vilades et al,17 and Miname et al.18 In all the studies, 16,17,18 nearly one quarter 
of heFH participants were found to have vessels that were greater than 50% obstructed.  Neefjes 
et al, 16 Vilades et al,17 and Miname et al,18 found significant obstruction in 24%, 26%, and 19% 
of heFH patients respectively.  Which is significantly greater than that of healthy adults, as 5% of 
Vilades et al,17 and 1% of Miname et al,18 were found to have significant obstruction.  Normal 
appearing arteries were found in only 16%, 50%, and 52% of heFH participants by Neefjes et al, 
16 Vilades et al,17 and Miname et al,18 respectively.  This is compared to 63% of healthy adults 
with normal arteries in Vilades et al,17 and 86% in Miname et al.18 
Agatston Score 
In the two studies17,18 that compared the Agatston scores in heFH populations to that of 
healthy adults, it was determined that heFH patients had higher CAC scores. Though, there was 
much variability between the two studies.17,18 Studies Neefjes et al,17 and Miname et al,18 
demonstrated a mean Agatston score of 51 and 55 respectively in the heFH participants.  
However, Vilades et al,17 found a mean score of 204 in the heFH population.  Only Neefjes et 
al,16 calculated the number of participants in the highest risk category >400, which was 23% of 
participants.  Vilades et al,17 also demonstrated a significant correlation of Agatston score with 
the presence of coronary artery diseases in the heFH group. 
Variables and CAD 
Across all three studies,16,17,18 the only variables that were significantly correlated with 
CAD as found on CTCA were HDL cholesterol and age.  LDL-c as well as total cholesterol 
levels were significantly correlated with CAD in studies by Neefjes et al,16 and Vilades et al.18  
Plaque Composition 
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Plaque composition was calculated in studies by Neefjes et al,16 and Miname et al.18 
Neefjes et al,16 found that in patients with heFH, most of the plaques detected on CTCA were 
calcified (54%).  Miname et al,18 also found that the majority of plaques in vessel segments were 
calcified in heFH participants, while healthy participants were most likely to have mixed plaques 
in vessel segments and had equal proportion of non-calcified and calcified plaques.   
DISCUSSION 
The studies16,17,18 reviewed do show higher rates of CAD detected in asymptomatic heFH 
patients. Not only are heFH participants more likely to have CAD, almost one quarter of them 
demonstrated >50% obstruction in at least one vessel. 16,17,18 For symptomatic patients, current 
AHA recommendations suggest percutaneous coronary intervention (PCI) in patients with 
obstruction >70%.  Though, currently guidelines do not recommend PCI in asymptomatic 
patients.11 According to Zhang et al,19 who studied 419 patients undergoing PCI for coronary 
stenosis, PCI did not reduce major adverse cardiac events in comparison with outpatient medical 
therapy in asymptomatic patients.  Based on these study19 findings, CTCA could be used to 
guide preventative and therapeutic treatment strategies for heFH patients, even though it is not an 
appropriate diagnostic test to indicate PCI. 
These studies16,17,18 do not focus explicitly on Agatston calcium score; however, they did 
report mean or median calcium scores for their study participants.  It is worth noting that Neefjes 
et al,16 found that 23% of their heFH population had calcium scores > 400.  This is significant 
because 400 is the CAC score at which CTCA readings become less accurate and tend to 
underestimate amount of obstruction present.11 Both studies, Vilades et al,17 and Miname et al,18 
found a significant correlation between calcium score and presence of CAD.  Although, the 
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presence of coronary plaque has only a weak correlation with the extent of stenosis.20,21 Thus 
limiting the ability of calcium score to report extent and severity of CAD. 
Previous studies22,23 have shown that non-calcified plaques show the strongest association 
for being the culprit lesions in acute coronary syndrome, and that calcified plaques are the least 
associated with ACS.  Of the studies16,17,18 reviewed, there were no statistically significant 
findings related to plaque composition when comparing healthy patients and heFH patients.  
There were some surprising findings as to other variables related to CAD.  All three 
studies16,17,18 found that low HDL was significantly correlated to CAD in heFH patients.  Neefjes 
et al,16 and Miname et al,18 found LDL-c levels and age to be related to CAD.  Surprisingly, 
other variables known for their association with CAD in non-heFH patients, such as smoking and 
diabetes had no significant correlation.11   
The studies examined in this systematic review had several limitations.  One limitation 
that effects all studies is that CTCA tends to overestimate or underestimate severity of CAD in 
patients with extensive calcified plaques, specifically in those with calcium scores greater that 
10, and severely in those >400. 11   Also, there was variability among participants as to weather 
or not they had previously or were currently undergoing statin therapy for hyperlipidemia.  
Though, there is no proven evidence to show that statin therapy modifies CAC evolution.7 Each 
study had limitations in its study population.  Population size is small in each of the reviewed 
studies.  Also, Neefjes et al,16 did not compare its heFH patients to healthy asymptomatic adult 
controls.   Age is also a limitation.  Though, the age range selected is based on known 
association of CAD and age, it excludes application of these findings to the very young and very 
old.  Lack of extended follow up limits the application of review results, as there were no 
measurements of adverse outcomes or major cardiac events as they relate to the amount of CAD 
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found in these asymptomatic patients.  Finally, though CTCA is growing in use, coronary 
angiogram  (cardiac catheterization) remains the gold standard for diagnosis of coronary artery 
disease and was not used in any study reviewed in this analysis.  
Further research is needed to justify the use of CTCA in asymptomatic heFH patients.  
Studies must include longer follow up to determine the associated risk of future major cardiac 
events based on CTCA in heFH patients as compared to healthy adults.  No studies exist that 
specifically target heFH patients that undergo prophylactic PCI, to predict outcomes specific to 
that patient population.   
CONCLUSION 
 This systematic review does indicate that there is a future for CTCA in the risk 
stratification of heFH patients.  CTCA has the ability to accurately tell us the extent of CAD in 
heFH patients, whom have been shown in this review as more likely to have asymptomatic CAD.  
If this information, when applied to treatment strategies, has the ability to reduce risk of acute 
coronary syndrome and mortality, remains to be discovered.   
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TABLE 1:  GRADE of Reviewed Studies 
Quality Assessment 
 Downgrade Criteria  
No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Quality Importance 
CT Coronary Angiographic Findings   
3 
 Observational  
Serious 
a,b,c,d,e Not seriousf Seriousg Not serious Not likely 
Very 
low Critical 
Agatson Calcium Score   
3 
 Observational  
Serious 
a,b,c,d,e Not serious
f Seriousg Not serious Not likely Very low Important 
Plaque Composition   
3 
 Observational  
Serious  
a,b,d,e Not serious
f Seriousg Not serious Not likely Very low Important 
 
aNo healthy adult control group studied in Neefjes et al.    
bDiabetic participants not excluded in  Medel et al. 
cVariability with what was considered obstruction: >50% in Neefjes et al and Miname et al; and >70% in Medel et al. 
dLength of current or previous statin use not accounted for 
eControl group much smaller than heFH group (35 and 102 respectively) 
fAgatson calcium score reported as mean in Neefjes et al, and median in Miname et al. and Medel et al.  
gTotal sample size in all three studies is lower than optimal 
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TABLE 2:  CCTA, Agatston Score and Plaque Composition Results 
Study Neefjes et al,16 Vilades et al,17 Miname et al,18 
 heFH (n = 140) 
Control 
(none) 
heFH 
(n = 50) 
Control 
(n = 70) 
heFH 
(n = 102) 
Control 
(n = 35) 
CCTA Findings 
Normal 23 (16%) ____ 25 (50%) 44 (62%) 53 (52%) 35 ( 86%) 
Obstructive Lesions 33 (24%) ____ 13 (26%) 4 (5%) 
20 (19%) 
 
 
1 (3%) 
 
 
Non-Obstructive 
Lesions 
84 (60%) 
 
 
____ 11 (22%) 19 (27%) 29 (28%) 4 (11%) 
Two Obstructive 
vessels 9 ____ ____ ____ ____ ____ 
Three Obstructive 
Vessels 4 ____ ____ ____ ____ ____ 
Agatston Score 
 51  mean ____ 
204 (35-450) 
median 
46 (45-76) 
median 
55 +/- 129 
(0-748) 
median 
38+/-140 
(0-666) 
median 
>400 32 (23%) ____ ____ ____ ____ ____ 
Plaque composition 
Non-Calcified 192 (25%) ____ ____ ____ 0.60 0.11 
Calcified 419 (54%) ____ ____ ____ 0.80 0.11 
Mixed 
 
163 (21%) ____ ____ ____ 0.63 0.20 
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TABLE 3:  Associated heFH participants characteristics with CAD 
Study Neefjes et al,16 Vilades et al,17 Miname et al,18 
 heFH (n = 140) 
Control 
(none) 
heFH 
(n = 50) 
Control 
(n = 70) 
heFH 
(n = 102) 
Control 
(n = 35) 
Variables related to presence of CAD  (Univariate analysis) 
Age 
p= .000 
___ 0 .01 ____ <0.0001 CI = (0.15 to 
0.50) 
Gender 
p= .003 
____ 0.159 ____ 0.43 CI = (-7.14 to 
-1.45) 
Smoker 
p= .532 
____ 0.535 ____ 0.24 CI = (-2.12 to 
4.10) 
Diabetes 
p= 0.822 
____ 0.527 (multivariate) ____ ______ CI= (-5.08 to 
6.39) 
Hypertension 
p= 0.125 
____ 0.497 ____ 0.55 CI = (-0.69 to 
5.64) 
BMI 
p= 0.038 
____ 0.434 ____ _____ CI = (0.02 to 
0.78) 
LDL 
(mmol/L) 
p= 0.029 
____ 0.467 ____ 0.0055 CI = (0.13 to 
2.31) 
HDL 
(mmol/L) 
p= 0.004 
____ 0.050 ____ 0.005 CI = (-9.12 to 
-1.82) 
Triglycerides 
(mmol/L) 
p= 0.467 
____ 0.365 ____ 0.13 CI = (0.60 to 
1.29) 
Tendon 
Xanthoma 
p= 0.077 
____ 0.488 ____ Achilles 0.026 CI = (-0.34 to 
6.38) 
Total 
Cholesterol 
p= 0.001 
____ 0.193 ____ 0.0003 CI = (0.01 to 
0.03) 
 
*Bold = statistically significant findings 
